Al-Ansari Essam, Du Hong-kai, Yu Lunyin, Ochoa Cristhiaan D, Garg Hari G, Quinn Deborah A, Hales Charles A
Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Chest. 2007 Dec;132(6):1898-905. doi: 10.1378/chest.06-0941.
We have shown previously that antiproliferative unfractionated heparins block hypoxia-induced pulmonary arterial hypertension (PAH) and vascular remodeling, and hypothesized that low-molecular-weight heparins (LMWHs) would too.
To determine the potential role and mechanisms of dalteparin and enoxaparin (two LMWHs) in inhibiting hypoxic PAH and vascular remodeling.
Male Hartley guinea pigs were exposed for 10 days to normobaric 10% oxygen with dalteparin (5 mg/kg), enoxaparin (5 mg/kg), or with an equivalent volume of normal saline solution. Normoxic control animals (n = 5) received room air for 10 days. Bovine pulmonary artery smooth-muscle cells (PASMCs) were grown in 10% fetal bovine serum without heparin, with dalteparin (1 microg/mL) or with enoxaparin (1 microg/mL).
Pulmonary arterial pressure (PAP), cardiac index, right ventricular heart weight divided by left ventricular plus septum weight (RV/LV+S), hematocrit, percentage of wall thickness of intraacinar vessels (%WT-IA), percentage of wall thickness of terminal bronchiole vessels (%WT-TA), and the percentage of thick-walled vessels (%Thick) were determined. In PASMCs, expression of p27 and cell growth were compared because in mice whole heparin depends on p27 for its antiproliferative action.
In hypoxic animals, hematocrit, PAP, total pulmonary vascular resistance index, RV/LV+S, %WT-IA, %WT-TA, and %Thick all rose significantly vs normoxic control animals (p < 0.05); cardiac index was unchanged. Dalteparin but not enoxaparin significantly reduced PAP, total pulmonary vascular resistance index, and RV/LV + S (p < 0.05 vs hypoxia alone); inhibited PASMC growth; and upregulated p27 expression. Enoxaparin moderately reduced vascular remodeling, which did not translate into less pulmonary hypertension.
Not all LMWHs are the same. Dalteparin was more effective than enoxaparin in inhibiting pulmonary hypertension and vascular remodeling in hypoxic guinea pigs.
我们之前已经表明,未分级的抗增殖肝素可阻断缺氧诱导的肺动脉高压(PAH)和血管重塑,并推测低分子量肝素(LMWHs)也会有同样的效果。
确定达肝素和依诺肝素(两种低分子量肝素)在抑制缺氧性PAH和血管重塑中的潜在作用及机制。
将雄性Hartley豚鼠暴露于常压10%氧气环境中10天,分别给予达肝素(5mg/kg)、依诺肝素(5mg/kg)或等量的生理盐水溶液。常氧对照组动物(n = 5)暴露于室内空气中10天。牛肺动脉平滑肌细胞(PASMCs)在不含肝素、含达肝素(1μg/mL)或含依诺肝素(1μg/mL)的10%胎牛血清中培养。
测定肺动脉压(PAP)、心脏指数、右心室重量除以左心室加室间隔重量(RV/LV+S)、血细胞比容、腺泡内血管壁厚度百分比(%WT-IA)、终末细支气管血管壁厚度百分比(%WT-TA)以及厚壁血管百分比(%Thick)。在PASMCs中,比较p27的表达和细胞生长情况,因为在小鼠中,全肝素的抗增殖作用依赖于p27。
与常氧对照组动物相比,缺氧动物的血细胞比容、PAP、总肺血管阻力指数、RV/LV+S、%WT-IA、%WT-TA和%Thick均显著升高(p < 0.05);心脏指数无变化。达肝素可显著降低PAP、总肺血管阻力指数和RV/LV + S(与单独缺氧相比,p < 0.05);抑制PASMC生长;并上调p27表达。依诺肝素可适度减轻血管重塑,但这并未转化为肺动脉高压的减轻。
并非所有低分子量肝素都相同。在抑制缺氧豚鼠的肺动脉高压和血管重塑方面,达肝素比依诺肝素更有效。